From the Editor

GSK’s position is raising concerns as it continues working towards its separation of businesses.

Bio/pharmaceutical manufacturers have made a good first step toward global vaccination through pledging doses at no- to low-profit rates.

As face masks start to come off, bio/pharma’s COVID-19 battle goes on.

The world of bio/pharma has been celebrating its achievements across a variety of categories in the latest rounds of awards.

Smart, accurate, science-based messaging is needed to advance bio/pharma science.

COVID-19 has placed bio/pharma in the spotlight of global media, but away from vaccines there are other prospective pipeline treatments that will be worth watching.

Bio/pharma works hard today to change the calendar to tomorrow.

More work is needed to ensure the rising demand for cell and gene therapy manufacturing capacity and required skilled workforce can be met in Europe.

COVID-19 vaccine supplies are breaking news headlines, in both ‘good’ and ‘not so good’ ways.

A complicated vaccination rollout and mixed messages may derail the pandemic endgame.

The outlook for the European pharma industry is appearing to be favourable overall.

Shutting down the COVID-19 pandemic requires a global, selfless effort.

After a difficult year, bio/pharma science delivers promising results.

Transparency and open-dialogue are vital to sway the vaccine-hesitant community.

Industry wants clarification on compliance following the end of the Brexit transition period.

Resolving drug shortages starts with identifying the source of the problem.

Misleading messages contribute to eroding trust in public health agencies.

European pharma companies may have a vested interest in the outcome of the US elections.

AstraZeneca has potentially taken poll position in the race to develop a novel coronavirus vaccine, but will AZD1222 be ready in 2020?

Amid high expectations for a vaccine, bio/pharma readies capacity, weighs pressures.

Time sure flies, except when you are waiting for something to happen.

COVID-19’s impact on the global economy is dealing a blow to merger and acquisition activity in the biopharma industry.

FDA Commissioner Hahn commits to a science-based review and approval process.

Achieving herd immunity will require testing, data, a vaccine, and public support.

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

As the coronavirus pandemic unfolds, Pharma must practice science over hype.

As COVID-19 rapidly spreads, the bio/pharma industry is committing significant efforts to fast track development of therapies.

Emergency action to protect patients and the drug supply may have long-term implications.

Despite increasing R&D budgets by bio/pharma companies, returns on this investment are reducing and the cost of bringing an asset to market is increasing.

Bio/pharma researchers mobilize to diagnose and treat patients in pandemic threat.